Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma

Blood Cancer J. 2020 Mar 2;10(3):25. doi: 10.1038/s41408-020-0297-2.

¹ Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece. mariagabria@gmail.com.
² Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
³ Department of Medical Research, 251 General Air Force Hospital, Athens, Greece.

^# Contributed equally.

No abstract available

Publication types